Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing.
about
IgE-based immunotherapy of cancer: challenges and chances.Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity.Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.Building better monoclonal antibody-based therapeutics.Exploitation of the Polymeric Immunoglobulin Receptor for Antibody Targeting to Renal Cyst Lumens in Polycystic Kidney Disease7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells.Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8.Immunoglobulin A: A next generation of therapeutic antibodies?Structure and function relationships in IgA.Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.Fc-fusion proteins: new developments and future perspectives.Upstream and downstream processing of recombinant IgA.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody.IgA EGFR antibodies mediate tumour killing in vivo.Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells.Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy.Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?Insights from Fc receptor biology: a route to improved antibody reagents.Radiolabelled polymeric IgA: from biodistribution to a new molecular imaging tool in colorectal cancer lung metastases.Impaired migration of IgA-secreting cells to colon adenocarcinomas.Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo.
P2860
Q33619979-EBDEB17B-2614-4347-AAEA-78EF79AC1C63Q34000700-C9721608-BFA4-4461-823A-25F7C6E70D8EQ34218284-76CA4454-6B24-438D-BD41-2EEFDA912199Q35569901-EC0685D8-2162-4EB1-9DFD-02D115095C35Q35817552-24855A87-3442-4765-8DD3-3FFBF59F56A0Q35860685-9FB4D0C5-BFCE-4415-90A1-98E22EA6C055Q35992488-3EC1E911-75E9-444B-BA8E-D2250A2BE692Q36127055-885B88DA-FD67-42E1-B0B1-5A9FE56F7C53Q36366594-AEE430E5-B6D6-4938-8ECE-C0007449AEC6Q36487349-73258F26-1A42-45DF-AFE8-D3DE080ACC4FQ37892323-243F129C-4E9C-48CF-B432-E52BA0DB682CQ37936765-17AB0445-10F3-4195-9B38-9CCA3197F733Q37964490-11640D50-BE88-4D63-BDFC-B1A2954040E6Q38029985-8725F85E-3D5F-4C4B-B343-05BD5D20229EQ38254478-4E7DD24C-A2C5-4F0B-A4D5-20C1541AFE39Q38717198-1D0EEFDE-2A76-4D93-9DF4-D521823694B9Q39027573-08BC0605-853B-4296-AF2B-25D186E21C6BQ39114924-84D06BA6-E4F6-4964-939F-D63E93F0EAE1Q39358478-4EE70A0D-32C3-4A0B-B611-F72B2CD645D7Q41704272-42A6A317-486F-41EB-8D2F-B8AFE19511EAQ42558684-0D7D8191-5FA3-453D-9827-DD2B6E9DA32CQ43177854-35EC9A14-6A6F-46E8-8E8D-5B69AAD3CEE4Q47114808-E0D34532-63E2-4460-BDA3-633303BBE802Q51065170-B07B4316-F395-4AE9-BFCD-73CD7CD2973DQ52648924-888306D5-BEAD-4A9D-B17E-2B8E3884D91D
P2860
Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Recombinant dimeric IgA antibo ...... effective tumor cell killing.
@en
Recombinant dimeric IgA antibo ...... effective tumor cell killing.
@nl
type
label
Recombinant dimeric IgA antibo ...... effective tumor cell killing.
@en
Recombinant dimeric IgA antibo ...... effective tumor cell killing.
@nl
prefLabel
Recombinant dimeric IgA antibo ...... effective tumor cell killing.
@en
Recombinant dimeric IgA antibo ...... effective tumor cell killing.
@nl
P2093
P356
P1476
Recombinant dimeric IgA antibo ...... e effective tumor cell killing
@en
P2093
Jan G J van de Winkel
Katja Klausz
Matthias Peipp
Michael Dechant
Stefan Lohse
Stefanie Derer
Thomas Beyer
Thomas Valerius
P304
P356
10.4049/JIMMUNOL.1003082
P407
P577
2011-02-11T00:00:00Z